Antidepressants and risk of prostate cancer: a nested case-control study.
Antidepressants and risk of prostate cancer: a nested case-control study.
复制标题
抗抑郁药和前列腺癌的风险：一项巢式病例对照研究。
DOI：
10.1038/sj.pcan.4501003
复制
发表时间：
2008
影响因子：
4.8
通讯作者：
Collet,J-P
中科院分区：
文献类型：
--
作者：
Tamim,HM;Mahmud,S;Hanley,JA;Boivin,J-F;Stang,MR;Collet,J-P
尽管抗抑郁药物的使用与癌症风险之间的关联在过去几年中受到了相当多的关注，但尚未专门针对前列腺癌进行研究。我们进行了一项基于人群的病例对照研究，以评估与三环类抗抑郁药（TCA）和选择性血清素再摄取抑制剂（SSRI）暴露相关的前列腺癌风险。 1981 年至 2000 年间，萨斯喀彻温省癌症机构累计诊断出 7,767 例前列腺癌病例。萨斯喀彻温省卫生局共确定了 31 068 名年龄和日历时间相匹配的男性对照者。 TCA 和 SSRI 暴露数据来自萨斯喀彻温省门诊处方药数据库，涵盖长达 24 年的时间。当诊断前 2-5 年接触 TCA 时，发现 TCA 使用与前列腺癌风险之间存在显着正相关，在低、中和高平均每日剂量水平下，比率比分别为 1.31、1.58 和 2.42。未发现接触 SSRIs 与前列腺癌风险显着相关。过去 2-5 年使用 TCA 与前列腺癌风险的剂量依赖性小幅增加有关。然而，检测偏差可能导致了观察到的关联。
Although the association between antidepressant drug use and risk of cancer has received considerable attention in the past years, no work has been done specifically on prostate cancer. We carried out a population-based case–control study to assess the risk of prostate cancer in association with exposure to tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). 7767 prostate cancer cases diagnosed between 1981 and 2000 were accrued through the Saskatchewan Cancer Agency. Saskatchewan Health identified a total of 31 068 male controls who were matched on age and calendar time. Data on exposure to TCAs and SSRIs were compiled from the Saskatchewan outpatient prescription drug database, and covered a period upto 24 years. A positive significant association was found between TCA use and risk of prostate cancer, when exposure took place 2–5 years before diagnosis, with rate ratios of 1.31, 1.58, and 2.42 at the low, medium and high average daily dose levels, respectively. Exposure to SSRIs was not found to be significantly associated with the risk of prostate cancer. TCA use 2–5 years in the past was associated with a small dose-dependent increase in the risk of prostate cancer. Nevertheless, detection bias could have contributed to the observed association.